Clinical Research Directory
Browse clinical research sites, groups, and studies.
Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease
Sponsor: The University of Queensland
Summary
The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.
Official title: Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2021-02-09
Completion Date
2025-12
Last Updated
2024-09-25
Healthy Volunteers
Yes
Interventions
Levetiracetam
Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
Placebo
Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
Locations (1)
University of Queensland Centre for Clinical Research
Brisbane, Queensland, Australia